Latest filings (excl ownership)
6-K
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
28 Oct 24
6-K
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
22 Oct 24
6-K
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
9 Oct 24
6-K
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
7 Oct 24
6-K
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
23 Sep 24
6-K
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024
19 Sep 24
6-K
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
4 Sep 24
6-K
Current report (foreign)
30 Aug 24
6-K
Form 6-K Report of Foreign Private Issuer for August, 2024
6 Aug 24
6-K
RELIEF THERAPEUTICS Holding SA Announces Results of
28 Jun 24
6-K
Invitation to the Annual Shareholders' Meeting of RELIEF THERAPEUTICS Holding SA
3 Jun 24
6-K
Relief Therapeutics Announces New Executive Leadership Team strengthening capabilities to guide the Company through pipeline development initiatives
10 May 24
20-F
2023 FY
Annual report (foreign)
30 Apr 24
6-K
Invitation to the Extraordinary Shareholders' Meeting of RELIEF THERAPEUTICS Holding SA
3 Apr 24
6-K
Form 6-K Report of Foreign Private Issuer for March, 2024
27 Mar 24
6-K
Form 6-K Report of Foreign Private Issuer for February, 2024
28 Feb 24
6-K
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
5 Dec 23
6-K
Relief Therapeutics Announces CEO Transition
22 Nov 23
6-K
Form 6-K Report of Foreign Private Issuer for October, 2023
10 Oct 23
6-K
Current report (foreign)
15 Sep 23
6-K
Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVAâ„¢ (ACER-001) with Acer Therapeutics
31 Aug 23
6-K
RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement
23 Jun 23
6-K
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders
20 Jun 23
6-K
RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders
1 Jun 23
20-F
2022 FY
Annual report (foreign)
12 May 23
6-K
Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
3 May 23
NT 20-F
Notice of late annual filing (foreign)
2 May 23
F-6 POS
Automatic registration for ADRs (post-effective amendment, foreign)
24 Apr 23
6-K
Current report (foreign)
17 Apr 23
6-K
Relief Therapeutics Announces Executive Leadership Team Change
5 Apr 23
6-K
Proposes a reverse stock split of its ordinary shares in preparation for planned listing to the Nasdaq Stock Market
4 Apr 23
6-K
Relief Therapeutics Provides an Update on its Financing Strategy
8 Feb 23
RW
Registration withdrawal request
7 Feb 23
F-1/A
Registration statement (foreign) (amended)
23 Dec 22
F-1/A
Registration statement (foreign) (amended)
15 Nov 22
F-6 POS
Automatic registration for ADRs (post-effective amendment, foreign)
21 Oct 22
6-K
Form 6-K Report of Foreign Private Issuer for October, 2022
14 Oct 22
6-K
2022 to Date Highlights and Key Milestones
15 Sep 22
F-1
Registration statement (foreign)
23 Aug 22
6-K
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
4 Aug 22
Latest ownership filings
No filings